Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
All entries in brain and CNS tumors
- Trial result Spotlight
Brain and CNS tumors
Cesium-131 collagen “GammaTile” brachytherapy cuts surgical-bed recurrence vs post-op SRT in resected brain mets
Cesium-131 collagen tile-based radiation therapy (TBRT; intraoperative brachytherapy that delivers focal radiation immediately after resection) was compared with standard post-operative stereotactic radiation therapy…
NCT04365374 - Trial result
Brain and CNS tumors
Lanreotide (somatostatin analog) shows disease stabilization in advanced PPGL in a Phase 2 preprint
Lanreotide depot/autogel is a long-acting somatostatin analog that targets somatostatin receptors (SSTRs) expressed on many pheochromocytomas/paragangliomas (PPGLs). In results reported as a medRxiv preprint, the…
NCT03946527 - New trial
Brain and CNS tumors
REMIND feasibility study tests a single maintenance IMRT fraction after temozolomide-based treatment in glioblastoma
University of Minnesota investigators are running REMIND as a small, single-center feasibility study of an additional low-dose radiation treatment after standard upfront treatment for newly diagnosed glioblastoma.…
NCT07831772 Exploratory - New trial
Brain and CNS tumors
Phase 1 nivolumab plus focused ultrasound and microbubbles tests blood-brain barrier opening in recurrent pediatric brain tumors
This open-label Phase 1 study from Children’s National Research Institute tests neuronavigation-guided low-intensity focused ultrasound with sulfur hexafluoride microbubbles (Lumason, Bracco) to transiently open the…
NCT07664176 Exploratory - New trial
Brain and CNS tumors
Phase 2 VISTA combines valproic acid, irinotecan, and simvastatin for recurrent malignant glioma
This prospective, open-label Phase 2 study from Inova Health Care Services evaluates a three-drug repurposed regimen in recurrent malignant glioma. Valproic acid has histone deacetylase-inhibitory and antiseizure…
NCT07831369 Exploratory - New trial
Brain and CNS tumors
Phase 3 NRG-CC017 tests pulsed radiation plus temozolomide to preserve cognition in glioblastoma
NRG Oncology’s randomized Phase 3 NRG-CC017 trial compares temporally modulated pulsed radiation therapy (TMPRT) with standard external-beam radiation in newly diagnosed, IDH-wildtype, MGMT-unmethylated glioblastoma.…
NCT07452458 Registrational - New trial
Brain and CNS tumors
Phase 1b NEO100 intranasal perillyl alcohol evaluates safety and drug exposure in selected pediatric brain tumors
NeOnc Technologies’ Phase 1b study evaluates intranasal NEO100, a highly purified formulation of perillyl alcohol, in patients aged 5-18 with protocol-defined pediatric high-grade gliomas and selected other malignant…
NCT06357377 Exploratory - Trial result
Brain and CNS tumors
TMZ-induced inflammatory remodeling exposes a ROCK vulnerability in recurrent GBM; fasudil improves survival in preclinical models
In a new preprint, temozolomide (TMZ; alkylating chemotherapy) was evaluated in a window-of-opportunity recurrent glioblastoma (GBM) cohort within NCT05236036: 4 patients received additional pre-op TMZ (150mg/m²/day…
NCT05236036 - New trial Spotlight
Brain and CNS tumors
Phase 1 SRN-101 intratumoral AAV–IFNβ immuno-gene therapy in recurrent high-grade glioma.
This first-in-human, single-arm, window-of-opportunity Phase 1 study tests SRN-101, an adeno-associated virus (AAV) gene therapy engineered to express interferon-beta (IFNβ) locally in tumor tissue, aiming to…
NCT07826949 First-in-human - New trial Spotlight
Brain and CNS tumors
Phase 2 safusidenib erbumine mutant-IDH1 inhibitor in post-vorasidenib progressive IDH1 glioma.
Nuvation Bio’s multicenter Phase 2 study tests safusidenib erbumine (250 mg orally twice daily), a brain-penetrant small-molecule inhibitor of mutant IDH1 (including IDH1 R132) that lowers the oncometabolite…
NCT07703436 Exploratory - New trial
Brain and CNS tumors
Early Phase 1 avutometinib dual RAF/MEK inhibitor + defactinib FAK inhibitor in newly diagnosed high-grade glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins is running an early-phase, open-label feasibility and safety study testing avutometinib (VS-6766), a dual RAF/MEK pathway inhibitor, plus defactinib…
NCT07778602 Exploratory - New trial
Brain and CNS tumors
Phase 1b/2 BreakVax personalized vaccine + PD-1/CTLA-4 checkpoint blockade in GBM
This Phase 1b/2, multicenter, open-label, single-arm study in adults with glioblastoma (GBM) tests a multi-component immunotherapy strategy anchored by BreakVax (BB-101), a per-patient designed/manufactured…
NCT07762716 Exploratory - New trial
Brain and CNS tumors
Phase 2 zanzalintinib MET/VEGFR/AXL/MER inhibitor in metastatic pheochromocytoma/paragangliom
This Phase 2, single-arm study at Dana-Farber Cancer Institute evaluates oral once-daily zanzalintinib (XL092) in patients with unresectable, progressive metastatic pheochromocytoma or paraganglioma (PPGL).…
NCT07714551 Exploratory - New trial
Brain and CNS tumors
Phase 1b NLG802 (indoximod prodrug; IDO/TDO-pathway immunometabolic modulator) + temozolomide in pediatric CNS tumors
This open-label Phase 1b, dose-escalation study evaluates escalating oral NLG802 (a prodrug of indoximod) given with oral temozolomide in children with relapsed/refractory primary brain and/or spinal tumors, aiming…
NCT07732413 Exploratory - New trial
Brain and CNS tumors
Phase 2 WSD0922-FU EGFR/EGFRvIII inhibitor plus adjuvant temozolomide in EGFR-mutant glioblastoma.
This randomized Phase 2 Mayo Clinic study tests whether adding WSD0922-FU—an oral, CNS-penetrant small-molecule inhibitor of EGFR and EGFRvIII—improves outcomes when combined with adjuvant temozolomide (an alkylating…
NCT07708961 Exploratory - Trial result
Brain and CNS tumors
Precision-guided SHH blockade (vismodegib) + HDAC inhibition (vorinostat) accompanies 9-year remission in relapsed SHH medulloblastoma
Vorinostat is an oral histone deacetylase (HDAC) inhibitor and vismodegib is an oral SMO inhibitor targeting the Sonic Hedgehog (SHH) pathway; together with curcumin (multi-target natural product with reported…
NCT02162732 - Trial result
Brain and CNS tumors
Pembrolizumab + HSPPC-96 misses 1-year OS endpoint in newly diagnosed GBM
Pembrolizumab is an anti–PD-1 antibody, and HSPPC-96 is a personalized tumor-derived HSP96-peptide vaccine designed to broaden antigen presentation. In a multi-institutional Phase 2 randomized, placebo-controlled…
NCT03018288 - Trial result
Brain and CNS tumors
WT1/PRAME/survivin trivalent TAA‑T cells show tolerable safety and rare long remissions in pediatric CNS tumors
ReMIND (NCT03652545) tested autologous, non–gene-engineered multi-antigen tumor-associated antigen–specific T cells (TAA‑Ts) targeting intracellular WT1, PRAME, and survivin, given systemically in an open-label Phase…
NCT03652545 - Trial result
Brain and CNS tumors
IDH1-vac (IDH1R132H peptide vaccine) links immune response to long OS in IDH1-mutant astrocytoma
IDH1-vac is a mutation-specific long-peptide vaccine targeting the shared clonal driver neoepitope IDH1R132H (MHC class II–restricted) and was integrated with standard-of-care chemoradiation in the multicenter,…
NCT02454634 - New trial Spotlight
Brain and CNS tumors
Phase 1 177Lu-DTPA-omburtamab compartmental radioimmunotherapy targets B7-H3 (CD276)
This Phase 1, dose-escalation compartmental radioimmunotherapy (cRIT) study tests intrathecal/intraventricular delivery of 177Lu-DTPA-omburtamab, a B7-H3 (CD276)-targeting murine monoclonal antibody chelated with…
NCT07698899 First-in-human - Trial result
Brain and CNS tumors
Vorasidenib (dual mutant IDH1/2 inhibitor) cuts seizure rates ~80% and delays QoL decline in INDIGO grade 2 glioma
Vorasidenib (VOR) is an oral, brain-penetrant dual inhibitor of mutant IDH1/2 evaluated vs placebo in the Phase 3 INDIGO trial (NCT04164901) in treatment-naïve (post-surgery only) grade 2 mIDH1/2 diffuse glioma…
NCT04164901 - Trial result Spotlight
Brain and CNS tumors
Cesium-131 tile brachytherapy (TBRT) slashes surgical-bed recurrence vs post-op SRT in resected brain mets
ROADS (NCT04365374) was an open-label, randomized Phase 3 trial across 32 US centers comparing resection + post-operative stereotactic radiation therapy (SRT; standard approach for cavity control) vs resection +…
NCT04365374 - Trial result
Brain and CNS tumors
Lu-177 dotatate PRRT (SSTR2-targeted) hits 69% PFS-6 in refractory intracranial meningioma; Ga-68 dotatate PET tracks response
[177Lu]Lu-DOTA-TATE (Lu-177 dotatate) is a somatostatin receptor 2 (SSTR2)–targeted peptide receptor radionuclide therapy (PRRT), paired here with exploratory [68Ga]Ga-DOTA-TATE PET as a functional imaging biomarker,…
NCT03971461 - Trial result
Brain and CNS tumors
Preoperative single-fraction SRS (≈16Gy) for resectable brain mets delivers ~82% 1-year local control with ~5% LMD in meta-analysis
Single-fraction preoperative stereotactic radiosurgery (SRS)—a high-dose, highly conformal radiation treatment delivered to an *intact* resectable brain metastasis immediately before planned surgery—was evaluated in…
NCT05341739 - Trial result Spotlight
Brain and CNS tumors
Vorasidenib (dual mutant IDH1/2 inhibitor) delivers ~50-month PFS and delays next intervention in grade 2 IDH-mutant glioma
Vorasidenib (VOR) is an oral, brain-penetrant dual inhibitor of mutant IDH1/2, evaluated in the global, randomized, double-blind Phase 3 INDIGO trial (NCT04164901) in residual/recurrent grade 2 IDH1/2-mutant…
NCT04164901 - Trial result
Brain and CNS tumors
Vorasidenib (dual mutant IDH1/2 inhibitor) cuts seizure rates ~80% and delays QoL decline in INDIGO grade 2 glioma
Vorasidenib (VOR) is an oral, brain-penetrant dual inhibitor of mutant IDH1/2 evaluated vs placebo in the Phase 3 INDIGO trial (NCT04164901) in treatment-naïve (post-surgery only) grade 2 mIDH1/2 diffuse glioma…
NCT04164901 - Trial result
Brain and CNS tumors
NeoVax (personalized neoantigen long-peptide vaccine + poly-ICLC) plus PD-1 blockade (pembrolizumab) extends OS signals in newly diagnosed GBM
NeoVax is a personalized synthetic long-peptide neoantigen vaccine (up to 20 patient-specific peptides) formulated with the TLR3 agonist adjuvant poly-ICLC, designed to prime mutation-specific T cells; here it was…
NCT02287428 - Trial result
Brain and CNS tumors
DOC1021 (dubodencel) DC vaccine expands memory T cells with low tox in GBM chemoradiation combo
DOC1021 is an autologous dendritic-cell immunotherapy made by tandem loading patient DCs with autologous tumor mRNA plus tumor lysate to drive broad antigen presentation and a cDC1-like, CD8+ effector program; in a…
NCT04552886 - Trial result
Brain and CNS tumors
CART‑EGFR‑IL13Rα2 (EGFR/IL13Rα2 bivalent CAR‑T) shows 12.0‑mo mOS with no late safety signals in recurrent GBM
Eighteen patients with recurrent EGFR-amplified GBM received a single intracerebroventricular dose of CART‑EGFR‑IL13Rα2, an autologous bivalent CAR‑T designed to recognize EGFR (806 epitope) and IL13Rα2 (Phase 1, 3+3…
NCT05168423 - Trial result
Brain and CNS tumors
Liposomal curcumin (LC) + RT/TMZ hits RP2D 350mg/m² with early survival signal in newly diagnosed IDH-wt GBM
Liposomal curcumin (LC) is an IV nano/liposomal curcumin formulation intended to improve curcumin exposure and modulate inflammatory/oxidative and oncogenic signaling (including kynurenine-pathway biology) alongside…
NCT05768919
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.